In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF) about Hemostemix’s recent “blockbuster” news release on collaborating with world famous Dr. James Shapiro to Treat Type 1 Diabetes and about trademarking “Your Fountain of Youth”.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas Smeenk said that Dr. James Shapiro is well known and respected for creating the Edmonton Protocol for the treatment of  Type 1 Diabetes. Thomas went on to provide an update on Hemostemix’s technology platform that uses stem cells from a patient’s own blood to treat the heart-damage following a heart attack. Providing an update on Hemostemix’s recently closed oversubscribed private placement, he went on to explain how Hemostemix has found a “Fountain of Youth.”

To watch the full interview, click here.

About Hemostemix Inc.

Hemostemix is a publicly traded autologous (utilizing the patient’s own stem cells) stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To learn more about Hemostemix Inc., click here.

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

There are many impressive companies around the world trying to solve the world’s problems and make this a better place to live. When the right group of people can find the right environment, tremendous results can happen. Today we are going to look at one of those situations – Sernova Corp. (TSXV: SVA | OTCQB: SEOVF). Sernova is a regenerative medicine therapeutics platform company developing technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

That’s quite a mouthful so let’s try and break that down a little. Sernova is a clinical-stage company developing products for the treatment of chronic debilitating diseases. They are working on commercially viable treatments for things like diabetes, hemophilia and neurological diseases with therapeutic cells placed into its proprietary Cell Pouch System, an implanted and scalable medical device.

Sernova’s is focusing on treating chronic diseases with regenerative medicine. Regenerative medicine can be described as the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. It provides the potential of a functional cure vs. masking the underlying disease and long-term treatment of symptoms with prescription medicines.

To that end, what has the market excited about Sernova is their Cell Pouch System, in particular its success in treating Diabetes. Effectively this is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. On Jan 15, 2021, the company announced positive preliminary safety and efficacy data from the ongoing U.S. Phase I/II Cell Pouch clinical trial for Type-1 Diabetes. In fact, one patient has now been insulin free (requiring no injectable insulin) for nine months with optimal glucose control.

This news vaulted the stock from $0.75 to over $2.00. The reason for the excitement over this news is that Sernova’s proposed solution for Type-1 Diabetes represents a potential commercial opportunity of $30 billion for the company. However, there are a lot more applications for the Cell Pouch System that Sernova is concurrently working on. They have completed a pre-clinical proof-of-concept for Hemophilia with a $10 billion estimated market size and have a clinical program under development for a Thyroid program with an estimated $2.2 billion market opportunity.

This is pretty impressive stuff but it’s by no means an overnight success story. The company began trading under the name Sernova in 2006 with the first positive results from a long-term study evaluating the Cell Pouch System in a pre-clinical model of diabetes in July 2010. This has been years in the making but is finally getting close to a deliverable, and hopefully very profitable, product.

If you or anyone you know is afflicted with any of these maladies, which therapeutic would you sign up for? An existing regime of regularly administered drugs or an implant that fixes the problem at source and requires little to no maintenance. I’m pretty sure I know what I’d sign up for assuming nothing discouraging arises from clinical trials.

With that said, there is currently no revenue being generated although they are receiving grant money to support their Diabetes research. The current burn rate is a modest $1.0 – $1.5 million per quarter and they have over $30 million of cash following a $23 million financing that closed Mar 1, 2021. So funding shouldn’t be an issue for the foreseeable future. The company has roughly 257 million shares outstanding with another 50+ million warrants making the current market cap a little over $400 million. This stock is now on the radar but with plenty of potential given the markets they are trying to tap into.